Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex (NYSE: TFX) has launched a national advertising campaign to promote the UroLift® System, an innovative, minimally invasive treatment for benign prostatic hyperplasia (BPH). This humorous campaign emphasizes the importance of health screenings for men and aims to encourage visits to urologists. BPH, which affects many aging men, can cause disruptive urinary symptoms. The UroLift® System has treated over 400,000 men globally, offering a solution without severe side effects like erectile dysfunction. The 5-year durability data shows a 2-3% surgical retreatment rate annually.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, its Chairman, President, and CEO, will speak at the 41st Annual J.P. Morgan Healthcare Conference. The event is set for January 10, 2023, at 3:00 p.m. PT in San Francisco, California. A live audio webcast and presentation slides will be accessible on the Teleflex investor website. Teleflex focuses on innovative solutions in various medical fields, including vascular access and emergency medicine. More information can be found at teleflex.com.
Liam Kelly, Chairman, President and CEO of Teleflex, will present at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 1:30 p.m. (ET). A live audio webcast of the presentation can be accessed via the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, with innovative solutions in vascular access, interventional cardiology, anesthesia, and more. For additional details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a worldwide recall of specific lots of its Gibeck® Iso-Gard® Filters due to potential risks including splitting or detaching during use, which could compromise patient air supply. The recall, which affects products manufactured between December 17, 2019, and March 26, 2022, was expanded after 38 complaints were reported, including 4 injuries related to patient desaturation, but no deaths or long-term injuries. The FDA classified the recall as Class I, indicating serious health risks associated with the affected filters.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, Chairman, President and CEO, will present at the Jefferies London Healthcare Conference on November 15, 2022, at 2:40 p.m. (GMT). A live audio webcast of the presentation will be accessible via the investor section of the Teleflex website. The company focuses on purpose-driven innovation to enhance healthcare, with a diverse portfolio that includes products for vascular access, interventional cardiology, and more. For more details, visit teleflex.com.
Teleflex announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2022 to shareholders on record by November 15, 2022. This decision underscores the company’s commitment to shareholder returns while continuing its focus on providing medical technologies that enhance patient care.
Teleflex announced Q3 2022 financial results with revenues of $686.8 million, representing a 1.9% decline year-over-year, partially offset by a 2.4% increase in constant currency. GAAP diluted EPS dropped to $2.16 from $4.20 in the prior year. The company lowered its GAAP revenue growth guidance to (0.75)% to 0.25% and adjusted diluted EPS guidance to $12.80 to $13.20. The acquisition of Standard Bariatrics aligns with its M&A strategy, contributing to revenue and margin growth.
Teleflex (NYSE: TFX) announced results from a new study published in the Journal of Endourology demonstrating that the UroLift® System is effective for treating benign prostatic hyperplasia (BPH), specifically in patients with obstructive median lobes. Compared to TURP, patients treated with UroLift experienced significantly greater symptom improvement, faster satisfaction, and fewer post-op catheterizations. The analysis combined outcomes from controlled trials and real-world settings, confirming the safety and effectiveness of the UroLift System.
Teleflex (NYSE: TFX) will hold a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third-quarter financial results and operational updates. Participants can pre-register via the provided link or join via a live audio webcast on the company’s website. An audio replay will be accessible after 11:00 a.m. ET on the same day. Teleflex specializes in medical technologies that enhance health outcomes, with a diverse portfolio spanning vascular access, anesthesia, and surgical care.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
